{"id":172679,"date":"2023-09-24T08:22:32","date_gmt":"2023-09-24T13:22:32","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/09\/superior-outcomes-seen-with-fixed-duration-ibrutinib-venetoclax-in-cll"},"modified":"2023-09-24T08:22:32","modified_gmt":"2023-09-24T13:22:32","slug":"superior-outcomes-seen-with-fixed-duration-ibrutinib-venetoclax-in-cll","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/09\/superior-outcomes-seen-with-fixed-duration-ibrutinib-venetoclax-in-cll","title":{"rendered":"Superior Outcomes Seen With Fixed-Duration Ibrutinib\/Venetoclax in CLL"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/superior-outcomes-seen-with-fixed-duration-ibrutinib-venetoclax-in-cll3.jpg\"><\/a><\/p>\n<p>In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.<\/p>\n<p>Patients treated with fixed-duration ibrutinib (Imbruvica) plus venetoclax (Venclexta) achieved higher undetectable minimal residual disease (uMRD), progression-free survival (PFS), and overall survival (OS) rates compared with chlorambucil plus obinutuzumab (Gazyva) across most genomic subgroups of chronic lymphocytic leukemia (CLL).1.<\/p>\n<p>Findings come from the phase 3 GLOW study (NCT03462719) in which data were presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). Patients treated with ibrutinib and venetoclax achieved a higher uMRD rate at 3 months (54.7%) after the end of treatment compared with patients treated with obinutuzumab and chlorambucil (39.0%), except patients with trisomy-12, IGLL5 mutation, and mutated immunoglobulin heavy-chain variable (mIGHV).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups. Patients treated with fixed-duration ibrutinib (Imbruvica) plus venetoclax (Venclexta) achieved higher undetectable minimal residual disease (uMRD), progression-free survival (PFS), and overall survival (OS) rates compared with chlorambucil plus obinutuzumab [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-172679","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/172679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=172679"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/172679\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=172679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=172679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=172679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}